Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 336-340

  Fujimoto, N ^a   Kubo, T ^a   Inatomi, H ^b   Bui, H T T ^a   Shiota, M ^c   Sho, T ^a   Matsumoto, T ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Munakata Suikoukai General Hospital   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen transportation; Castration resistance; Polymorphism; SLCO

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CHINESE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO2B1 GENE; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORCHIECTOMY; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84887616120     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.23     Document Type: Article

References (38)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
2. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 35: 1513-1520.
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
4. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
5. Golshayan AR, Antonarakis ES. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013; 8: 27-35.
6. Hafeez S, Parker C. Radium-223 for the treatment of prostate cancer. Expert Opin Investig Drugs 2013; 22: 379-387.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
8. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009; 15: 3251-3255.
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
10. Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y et al. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormoneresistance of prostate cancer cells. Cancer Invest 2007; 25: 32-37.
11. Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies. Prostate 2011; 71: 550-557.
12. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443.
13. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008; 14: 3312-3318.
14. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29: 2565-2573.
15. Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011; 6: e20372.
16. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2011; 20: 619-627.
17. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008; 102: 617-621.
18. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193.
19. Holmes Jr L, Chan W, Jiang Z, Ward D, Essien EJ, Du XL. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer. Cancer Control 2009; 16: 176-185.
20. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 2006; 21: 165-169.
21. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007; 81: 76-82.
22. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63: 1161-1169.
23. dbSNP http://www.ncbi.nlm.nih.gov/snp?term.
24. Laitinen A, Niemi M. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population. Basic Clin Pharmacol Toxicol 2011; 108: 9-13.
25. Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet 2011; 26: 280-287.
26. Inatomi H, Katoh T, Kawamoto T, Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 1999; 6: 446-454.
27. Ikuyama T, Hamasaki T, Inatomi H, Katoh T, Muratani T, Matsumoto T. Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. Endocr J 2002; 49: 433-438.
28. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T et al. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol 2003; 10: 167-173.
29. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol 2011; 59: 572-583.
30. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306-4313.
31. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
32. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor resistance. Cancer Res 2008; 68: 5469-5477.
33. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313.
34. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69: 4434-4442.
35. Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Targets 2011; 11: 870-881.
36. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
37. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
38. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71: 6503-6513.